Drug Profile
BR 3001
Alternative Names: BR3001Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Diabetes-mellitus in South Korea
- 05 Apr 2018 Early research in Diabetes mellitus in South Korea (unspecified route)